The application of mathematical modelling to the design of bispecific monoclonal antibodies

por van Steeg, Tamara J., Bergmann, Kirsten Riber, Dimasi, Nazzareno, Sachsenmeier, Kris F., Agoram, Balaji
Publicado 2016

Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

por Mazor, Yariv, Sachsenmeier, Kris F., Yang, Chunning, Hansen, Anna, Filderman, Jessica, Mulgrew, Kathy, Wu, Herren, Dall’Acqua, William F.
Publicado 2017

Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action

por Geoghegan, James C., Diedrich, Gundo, Lu, Xiaojun, Rosenthal, Kim, Sachsenmeier, Kris F., Wu, Herren, Dall'Acqua, William F., Damschroder, Melissa M.
Publicado 2016

CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells

por Lupia, Michela, Angiolini, Francesca, Bertalot, Giovanni, Freddi, Stefano, Sachsenmeier, Kris F., Chisci, Elisa, Kutryb-Zajac, Barbara, Confalonieri, Stefano, Smolenski, Ryszard T., Giovannoni, Roberto, Colombo, Nicoletta, Bianchi, Fabrizio, Cavallaro, Ugo
Publicado 2018

Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling

por Sandercock, Alan M., Rust, Steven, Guillard, Sandrine, Sachsenmeier, Kris F., Holoweckyj, Nick, Hay, Carl, Flynn, Matt, Huang, Qihui, Yan, Kuan, Herpers, Bram, Price, Leo S., Soden, Jo, Freeth, Jim, Jermutus, Lutz, Hollingsworth, Robert, Minter, Ralph
Publicado 2015

Secretome screening reveals immunomodulating functions of IFNα-7, PAP and GDF-7 on regulatory T-cells

por Ding, Mei, Malhotra, Rajneesh, Ottosson, Tomas, Lundqvist, Magnus, Mebrahtu, Aman, Brengdahl, Johan, Gehrmann, Ulf, Bäck, Elisabeth, Ross-Thriepland, Douglas, Isaksson, Ida, Magnusson, Björn, Sachsenmeier, Kris F., Tegel, Hanna, Hober, Sophia, Uhlén, Mathias, Mayr, Lorenz M., Davies, Rick, Rockberg, Johan, Schiavone, Lovisa Holmberg
Publicado 2021

Targeting CD73 in the tumor microenvironment with MEDI9447

por Hay, Carl M., Sult, Erin, Huang, Qihui, Mulgrew, Kathy, Fuhrmann, Stacy R., McGlinchey, Kelly A., Hammond, Scott A., Rothstein, Raymond, Rios-Doria, Jonathan, Poon, Edmund, Holoweckyj, Nick, Durham, Nicholas M., Leow, Ching Ching, Diedrich, Gundo, Damschroder, Melissa, Herbst, Ronald, Hollingsworth, Robert E., Sachsenmeier, Kris F.
Publicado 2016

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

por Lim, Emerson A., Bendell, Johanna C., Falchook, Gerald S., Bauer, Todd M., Drake, Charles G., Choe, Jennifer H., George, Daniel J., Karlix, Janet L., Ulahannan, Susanna, Sachsenmeier, Kris F., Russell, Deanna L., Moorthy, Ganesh, Sidders, Ben S., Pilling, Elizabeth A., Chen, Huifang, Hattersley, Maureen M., Das, Mayukh, Kumar, Rakesh, Pouliot, Gayle P., Patel, Manish R.
Publicado 2022